NCT05980481View on ClinicalTrials.gov

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

July 10, 2025

Study Completion Date

October 10, 2026

Conditions
Gastric Cancer
Interventions
DRUG

RC48-ADC（2.5mg/kg）

2.5 mg/kg intravenous infusion every 2 weeks

DRUG

Trastuzumab

First load dose is 8.0mg , then 6.0 mg/kg intravenous infusion every 3 weeks

DRUG

Toripalimab

3.0 mg/kg intravenous infusion every 2 weeks

DRUG

Oxaliplatin（130mg/m2 ）

130mg/m2 intravenous infusion Q3W

DRUG

Capecitabine（1000mg/m2）

1000mg/m2 per os Q3W

DRUG

RC48-ADC（2.0mg/kg）

2.0 mg/kg intravenous infusion every 2 weeks

DRUG

Capecitabine（750mg/m2）

750mg/m2 per os Q3W

DRUG

Oxaliplatin（100mg/m2 ）

100mg/m2 intravenous infusion Q3W

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT05980481 - A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | Biotech Hunter | Biotech Hunter